echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Urol: 18F-DCFPyL-PET/CT can accurately detect and locate the metastases of prostate cancer

    J Urol: 18F-DCFPyL-PET/CT can accurately detect and locate the metastases of prostate cancer

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The current conventional imaging methods, including enhanced CT, MRI, and 99mTc-methylene bisphosphonate (MDP) bone imaging, are not ideal methods for detecting metastatic sites of metastatic prostate cancer (PCa) in different states.


    OSPREY is a prospective trial designed to determine the diagnostic performance of 18F-DCFPyL-PET/CT in detecting metastatic prostate cancer .


    It intended to identify 18F-DCFPyL-PET / CT in the detection of metastatic prostate cancer site diagnostic performance aimed at determining 18F-DCFPyL-PET / CT in the detection of metastatic prostate cancer site diagnosis performance diagnostic

    Two groups of patients underwent 18F-DCFPyL-PET/CT examination: Group A included high-risk PCa patients who underwent radical prostatectomy and pelvic lymphadenectomy; Group B included pre-PCa patients who were suspected of recurrence/metastasis by routine imaging examination.


    A total of 385 patients were included.


    In group A (252 evaluable subjects), the median specificity of 18F-DCFPyL-PET/CT in detecting pelvic lymph node metastasis was 97.


    In group B (n=93, median PSA was 11.


    In group B (n=93, median PSA was 11.


    The specificity of PSMA-targeted PET/CT to detect metastatic prostate cancer reached the predetermined primary endpoint, but the sensitivity did not.


    Original source:

    Pienta Kenneth J, Gorin Michael A, Rowe Steven P et al.


    org/10.
    1097/JU.
    0000000000001698" target="_blank" rel="noopener">A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET / CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.